SCHEDULE: RA Capital Discloses 9.9% Stake in Century Therapeutics
Beneficial Ownership Report
RA Capital Management and its affiliates have reported a 9.9% beneficial ownership stake in Century Therapeutics, Inc., following a recent private placement.
Summary
- RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed a Schedule 13G regarding Century Therapeutics, Inc.
- The Reporting Persons beneficially own an aggregate of 17,944,649 shares of Century Therapeutics, Inc. common stock.
- This ownership represents 9.9% of the company's outstanding common stock, which was rounded down from 9.99% due to EDGAR system limitations.
- The stake includes 17,754,430 directly held common shares, pre-funded warrants exercisable for up to 8,332,526 shares, and common warrants exercisable for up to 13,043,478 shares.
- A "Beneficial Ownership Blocker" provision in the warrants prevents their exercise if it would result in ownership exceeding 9.99% of the outstanding common stock.
- The percentage calculation is based on 87,405,311 shares outstanding as of November 25, 2025, plus 92,030,595 shares issued in a private placement on January 9, 2026, and 190,219 shares currently issuable from warrants.
- RA Capital Management, as the investment adviser, holds shared voting and dispositive power over the reported securities.
Sentiment
Score: 7
Explanation: The filing indicates a significant institutional investment by a reputable healthcare fund, which is generally a positive signal for the company. The 'beneficial ownership blocker' is a minor constraint but does not detract significantly from the overall positive sentiment of a large stake being taken.
Positives
- Significant institutional investment from RA Capital Management, a specialized healthcare investor, signals confidence in Century Therapeutics.
- The acquisition of a substantial stake (9.9%) by a prominent investment firm can attract further investor interest and potentially stabilize the stock.
Negatives
- The "Beneficial Ownership Blocker" limits RA Capital's ability to increase its stake beyond 9.99% through warrant exercise, potentially capping their influence or future investment flexibility.
Risks
- The "Beneficial Ownership Blocker" in the warrants limits the extent to which RA Capital and its affiliates can exercise their warrants, capping their potential ownership at 9.99% of the common stock outstanding.
Industry Context
The filing indicates a significant investment by a specialized healthcare fund, RA Capital Management, into Century Therapeutics, a biotechnology company. This type of institutional investment is common in the biotech sector, where specialized funds often take substantial positions in promising early to mid-stage companies, providing capital and signaling confidence to the broader market.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Restriction | Warrants held by RA Capital Healthcare Fund, L.P. contain a 'Beneficial Ownership Blocker' provision, precluding exercise to the extent that, following exercise, the Fund and its affiliates would own more than 9.99% of the common stock outstanding. | N/A | This provision limits the potential for RA Capital to increase its stake beyond 9.99% through warrant exercise, potentially impacting its long-term influence or investment strategy in Century Therapeutics. |
Stakeholder Impact
- Shareholders: The significant stake by RA Capital Management, a specialized healthcare investor, may be viewed positively, potentially increasing investor confidence and attracting further institutional interest. The beneficial ownership blocker ensures no single entity gains excessive control through warrant exercise beyond the 9.99% threshold.
- Company Management: The investment provides capital and validation from a sophisticated investor, potentially influencing strategic decisions and corporate governance discussions.
Key Dates
| Date | Description |
|---|---|
| 2025-11-25 | Date as of which 87,405,311 shares of common stock were outstanding, as reported in the Issuer's definitive proxy statement. |
| 2025-12-02 | Date of filing of the Issuer's definitive proxy statement with the SEC. |
| 2026-01-09 | Date of event requiring the filing of this statement, which is also the closing date of a private placement of equity securities by the Issuer. |
| 2026-01-16 | Date the Schedule 13G and Joint Filing Agreement were signed. |
Recommendation
holdThe filing indicates a substantial institutional investment by RA Capital Management, a respected healthcare fund, which is a positive signal for Century Therapeutics. However, a Schedule 13G primarily reports ownership and does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The existing 'beneficial ownership blocker' also caps the immediate upside from RA Capital's warrant exercise. Investors should 'hold' and await further operational updates or financial results to make a more informed decision, while acknowledging the positive signal of institutional backing.
Keywords
Century Therapeutics, RA Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Warrants, Private Placement, Biotechnology, Healthcare Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.